EP1199 Validation of Turkish version of Eastern Cooperative Oncology Group Performance Status (ECOG-PS) for gynecologic oncology patients

Introduzione: Questo studio si propone di valutare retrospettivamente la gestione dell’iter diagnostico e terapeutico e dell’outcome clinico di una casistica di pazienti anziani seguiti presso gli Ospedali di Alessandria e di Casale Monferrato. Metodologia: Da un totale di 343 pazienti affetti da MPM, trattati tra gennaio 2005 a novembre 2011 presso l’Ospedale SS. Antonio e Biagio e Cesare Arrigo di Alessandria e l’Ospedale SS. Spirito di Casale Monferrato, ne sono stati selezionati 124 aventi età ≥70 anni. Per ogni paziente sono stati analizzati: età, esposizione all’amianto, sesso, istologia, stadio, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), Charlson Comorbidity Index (CCI) e trattamento eseguito. Risultati: La sopravvivenza globale (OS) mediana è stata di 9 mesi. L’istotipo più frequente è risultato quello epitelioide (59%). L’esposizione all’amianto è stata documentata nel 96% dei casi. La diagnosi di MPM è stata documentata mediante esame istologico nel 91% dei pazienti (tasso di diagnosi istologica dai dati del Registro Italiano Mesotelioma decisamente minore). Lo stadio alla diagnosi nella maggior parte dei casi (60%) è riportato come I-II. L’ECOG-PS di questa casistica è risultato tra 0 e 1 nella quasi totalità dei casi, confermando come l’età anziana non sia sinonimo di scarso performance status. Non si sono osservate comorbidità maggiori nel 64% dei casi, mentre uno score medio di 4 e 5 è stato riscontrato rispettivamente nel 18% e nel 10% dei casi. L’analisi di sopravvivenza ha mostrato un impatto negativo sulla OS mediana in presenza di un CCI ≥4. Una chemioterapia basata su pemetrexed in questa popolazione anziana è risultata fattibile e con profilo di tossicità più che accettabile. Conclusione: Questo studio ha dimostrato l’influenza anche nella popolazione anziana di alcuni fattori prognostici come il sottotipo istologico, lo stadio IMIG, la presenza di comorbidità secondo CCI, la terapia con regimi pemetrexed-based o non pemetrexed-based. Sulla base di queste analisi è necessaria una maggiore attenzione verso questa categoria di pazienti, auspicando la possibilità di condurre studi prospettici rivolti anche alla popolazione anziana.

Download Full-text

Comprehensive Geriatric Assessment Adds Information to Eastern Cooperative Oncology Group Performance Status in Elderly Cancer Patients: An Italian Group for Geriatric Oncology Study

Journal of Clinical Oncology ◽

10.1200/jco.2002.20.2.494 ◽

2002 ◽

Vol 20 (2) ◽

pp. 494-502 ◽

Cited By ~ 291

Author(s):

Lazzaro Repetto ◽

Lucia Fratino ◽

Riccardo A. Audisio ◽

Antonella Venturino ◽

Walter Gianni ◽

...

Keyword(s):

Cancer Patients ◽

Geriatric Assessment ◽

Comprehensive Geriatric Assessment ◽

Daily Living ◽

Group Performance ◽

Performance Status ◽

Eastern Cooperative Oncology Group ◽

Geriatric Oncology ◽

Oncology Group ◽

Elderly Cancer Patients

PURPOSE: To appraise the performance of Comprehensive Geriatric Assessment (CGA) in elderly cancer patients (≥ 65 years) and to evaluate whether it could add further information with respect to the Eastern Cooperative Oncology Group performance status (PS). PATIENTS AND METHODS: We studied 363 elderly cancer patients (195 males, 168 females; median age, 72 years) with solid (n = 271) or hematologic (n = 92) tumors. In addition to PS, their physical function was assessed by means of the activity of daily living (ADL) and instrumental activities of daily living (IADL) scales. Comorbidities were categorized according to Satariano’s index. The association between PS, comorbidity, and the items of the CGA was assessed by means of logistic regression analysis. RESULTS: These 363 elderly cancer patients had a good functional and mental status: 74% had a good PS (ie, lower than 2), 86% were ADL-independent, and 52% were IADL-independent. Forty-one percent of patients had one or more comorbid conditions. Of the patients with a good PS, 13.0% had two or more comorbidities; 9.3% and 37.7% had ADL or IADL limitations, respectively. By multivariate analysis, elderly cancer patients who were ADL-dependent or IADL-dependent had a nearly two-fold higher probability of having an elevated Satariano’s index than independent patients. A strong association emerged between PS and CGA, with a nearly five-fold increased probability of having a poor PS (ie, ≥ 2) recorded in patients dependent for ADL or IADL. CONCLUSION: The CGA adds substantial information on the functional assessment of elderly cancer patients, including patients with a good PS. The role of PS as unique marker of functional status needs to be reappraised among elderly cancer patients.

Download Full-text

Performance Status Assessment by Using ECOG (Eastern Cooperative Oncology Group) Score for Cancer Patients by Oncology Healthcare Professionals

Case Reports in Oncology ◽

10.1159/000503095 ◽

2019 ◽

Vol 12 (3) ◽

pp. 728-736 ◽

Cited By ~ 9

Author(s):

Faisal Azam ◽

Muhammad Farooq Latif ◽

Ayesha Farooq ◽

Syed Hammad Tirmazy ◽

Saad AlShahrani ◽

...

Keyword(s):

Health Care Professionals ◽

Karnofsky Performance Status ◽

Performance Status ◽

Eastern Cooperative Oncology Group ◽

Treatment Decision ◽

Oncology Group ◽

Group Score ◽

Clinical Scenarios ◽

Status Assessment ◽

Ecog Ps

Medical literature does not have clear consensus on inter-rater reliability of PS assessment by different oncology health care professionals (HCPs) although it plays an important role in treatment decision and prognosis for oncology patients. Eastern Cooperative Oncology Group (ECOG) and Karnofsky performance status (KPS) scores are commonly used for this purpose by oncology HCPs around the world. This study was conducted to find variability or similarities in assessment of PS among the different oncology HCPs. A survey based on four hypothetical clinical scenarios was devised and sent to 50 oncology HCPs to assess the PS using ECOG PS tool. No significant variations in PS assessment by oncology HCPs was noted in our study sample.

Download Full-text

Complications following symptom-limited thoracentesis using suction

European Respiratory Journal ◽

10.1183/13993003.02356-2019 ◽

2020 ◽

Vol 56 (5) ◽

pp. 1902356 ◽

Cited By ~ 3

Author(s):

Ala Eddin S. Sagar ◽

Maria F. Landaeta ◽

Andres M. Adrianza ◽

Grecia L. Aldana ◽

Leonardo Pozo ◽

...

Keyword(s):

Pleural Fluid ◽

Group Performance ◽

Performance Status ◽

Eastern Cooperative Oncology Group ◽

Chest Discomfort ◽

Mediastinal Shift ◽

Increased Risk ◽

Procedural Complications ◽

Ecog Ps ◽

Current Guidelines

BackgroundThoracentesis using suction is perceived to have increased risk of complications, including pneumothorax and re-expansion pulmonary oedema (REPO). Current guidelines recommend limiting drainage to 1.5 L to avoid REPO. Our purpose was to examine the incidence of complications with symptom-limited drainage of pleural fluid using suction and identify risk factors for REPO.MethodsA retrospective cohort study of all adult patients who underwent symptom-limited thoracentesis using suction at our institution between January 1, 2004 and August 31, 2018 was performed, and a total of 10 344 thoracenteses were included.ResultsPleural fluid ≥1.5 L was removed in 19% of the procedures. Thoracentesis was stopped due to chest discomfort (39%), complete drainage of fluid (37%) and persistent cough (13%). Pneumothorax based on chest radiography was detected in 3.98%, but only 0.28% required intervention. The incidence of REPO was 0.08%. The incidence of REPO increased with Eastern Cooperative Oncology Group performance status (ECOG PS) ≥3 compounded with ≥1.5 L (0.04–0.54%; 95% CI 0.13–2.06 L). Thoracentesis in those with ipsilateral mediastinal shift did not increase complications, but less fluid was removed (p<0.01).ConclusionsSymptom-limited thoracentesis using suction is safe even with large volumes. Pneumothorax requiring intervention and REPO are both rare. There were no increased procedural complications in those with ipsilateral mediastinal shift. REPO increased with poor ECOG PS and drainage ≥1.5 L. Symptom-limited drainage using suction without pleural manometry is safe.

Download Full-text

Prognostic factors of ado-trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer

Journal of Oncology Pharmacy Practice ◽

10.1177/1078155220924088 ◽

2020 ◽

pp. 107815522092408 ◽

Cited By ~ 1

Author(s):

Deniz Tataroglu Ozyukseler ◽

Mustafa Basak ◽

Seval Ay ◽

Aygül Koseoglu ◽

Serdar Arıcı ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Group Performance ◽

Performance Status ◽

Eastern Cooperative Oncology Group ◽

Progression Free Survival ◽

Trastuzumab Emtansine ◽

Oncology Group ◽

Cancer Antigen ◽

Free Survival

Background Ado-trastuzumab emtansine is an antibody-drug conjugate that combines the cytotoxic activity of emtansine with human epidermal growth factor receptor 2-targeted antitumor features of trastuzumab. Objective We conducted a study of metastatic breast cancer patients treated with trastuzumab emtansine. By evaluating progression-free survival, overall survival, and response rates, we aimed to find prognostic factors of trastuzumab emtansine treatment. Methods Our study is a single-center, retrospective, observational study. We have clinical data from 78 patients treated with trastuzumab emtansine for metastatic breast cancer, from May 2016 through May 2019, at Kartal Dr Lutfi Kirdar Education and Research Hospital, Medical Oncology Department. Our objective is to assess the survival and response rates in trastuzumab emtansine-treated individuals and the factors associated with survival. The factors we analyzed were cancer antigen 15-3 sensitivity, Eastern Cooperative Oncology Group-Performance Status, presence or absence of visceral metastases, presence or absence of cranial metastases, and treatment-associated thrombocytopenia. Results Among 78 patients, median progression-free survival was 7.8 months, and overall survival was 21.1 months. Twenty of the patients had an objective tumor response. The results showed that trastuzumab emtansine was tolerable with a manageable safety profile and consistent with the results of the previous literature. Mostly seen adverse events were anemia, thrombocytopenia, fatigue, and increased levels of alkaline phosphatase. Patients with Eastern Cooperative Oncology Group-Performance Status = 2 had worse progression-free survival and overall survival compared to ones with Eastern Cooperative Oncology Group-Performance Status < 2; progression-free survival and overall survival are worse in cancer antigen 15-3-sensitive breast cancer patients. According to our findings, treatment-associated thrombocytopenia was a significant prognostic factor for survival. Patients with thrombocytopenia had 12 months progression-free survival, whereas patients without thrombocytopenia had only 4.1 months progression-free survival. In like manner, overall survival was much better in the thrombocytopenia-experienced patients as 29.5 versus 11.8 months. Conclusions Trastuzumab emtansine prolongs progression-free survival and overall survival with a manageable safety profile. Thrombocytopenia, Eastern Cooperative Oncology Group-Performance Status, and cancer antigen 15-3 are correlated with progression-free survival and/or overall survival.

Download Full-text